Eleven Biotherapeutics major shareholder Jafco Super V3 Investment Limi Sells 2,000 Shares (EBIO)
Eleven Biotherapeutics (NASDAQ:EBIO) major shareholder Jafco Super V3 Investment Limi sold 2,000 shares of the stock on the open market in a transaction dated Tuesday, August 26th. The stock was sold at an average price of $11.54, for a total value of $23,080.00. Following the transaction, the insider now directly owns 2,119,526 shares of the company’s stock, valued at approximately $24,459,330. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of Eleven Biotherapeutics (NASDAQ:EBIO) traded down 3.06% on Thursday, hitting $10.77. 586 shares of the company’s stock traded hands. Eleven Biotherapeutics has a 1-year low of $9.502 and a 1-year high of $19.333. The stock’s 50-day moving average is $11.70 and its 200-day moving average is $12.94. The company’s market cap is $165.8 million.
Eleven Biotherapeutics (NASDAQ:EBIO) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.51) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.47) by $0.04. On average, analysts predict that Eleven Biotherapeutics will post $-1.84 earnings per share for the current fiscal year.
Eleven Biotherapeutics, Inc, is a United States-based company, which develops protein-based biotherapeutics.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.